Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — Q2 2026 Earnings Presentation
25 slides from Jazz Pharmaceuticals's earnings presentation, Aug 3, 2026
Slide 1: 2026 Second Quarter Financial Results
August 3, 2026 2026 Second Quarter Financial Results Redefining Possibilities in Rare Disease
Slide 2: Caution Concerning Forward-Looking Statements
Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements related to: sales growth for the company’s combined rare oncology and epilepsy franchises in 2026, Xywav sales
Slide 3: Non-GAAP Financial Measures
Transforming Lives. Redefining Possibilities. Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with U.S. GAAP, the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presen
Slide 4: Introduction and Overview
Introduction and Overview Renee Gala President and Chief Executive Officer 4 August 3, 2026
Slide 5: Strong Execution Across Franchises Drives 2026 Revenue Guidance Increase
Strong Execution Across Franchises Drives 2026 Revenue Guidance Increase 2Q26 Execution Financial Upcoming Highlights Strength Milestones Commercial: Robust 2Q26: • Ready to launch zanidatamab in GEA; PDUFA date • Xywav (+13% YoY) • Record quarterly revenues of $1.2B (+16% YoY) of August 25, 2026 •
Slide 6: Commercial Performance
Commercial Performance Sam Pearce Executive Vice President and Chief Commercial Officer 6 August 3, 2026
Slide 7: Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity
Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity • Xywav revenue grew 13% YoY in 2Q26; continued momentum with 525 net patient adds in 2Q26 16,600 17,125 15,675 16,175 5,850 • Benefits of highly efficacious and safer treatment option due to reduced 15,225 5,525 4,950 5,225 sodium
Slide 8: Epidiolex: Development Opportunities for Durable Growth
Epidiolex: Development Opportunities for Durable Growth Epidiolex is the #1 branded epilepsy treatment1 +16% YoY • Continued commercial momentum with $292M in 2Q26 revenue Growth opportunities: $292 • Expanded Epidiolex development opportunities with multiple new clinical trials Net product sales ($
Slide 9: Zanidatamab: De-Risked Near-Term Opportunity
Zanidatamab: De-Risked Near-Term Opportunity Goal to be the HER2-targeted agent of choice • Ready to launch in 1L GEA on or before PDUFA date of August 25, 2026 • Customer-facing team in place and prepared for launch Other HER2-Expressing Cancers Breast Cancer Broad potential beyond BTC, GEA and BC
Slide 10: Ready for GEA Launch
Ready for GEA Launch Focus Areas at Launch 1. Clinical Education & Differentiation 2. Accelerated Market Access Establishing the new standard of care: Ziihera + tislelizumab Leveraging immediate reimbursement: Utilize established, as foundational backbone for HER2+ mGEA, independent of permanent J-c
Slide 11: Modeyso: Strong Initial Uptake and Early Launch Success
Modeyso: Strong Initial Uptake and Early Launch Success 1 2 3 Disease State Awareness Branded Campaign Launch Launch Exceeding Expectations & Education Strong HCP awareness and CNS WHO Grade 4 glioma1 focus on testing driving The most aggressive form increasing breadth of adoption of glioma Invariab
Slide 12: Zepzelca: Focused on 1LM ES-SCLC
PIPELINE Zepzelca: Focused on 1LM ES-SCLC +42% YoY (Driven by 1LM uptake) FDA approved Zepzelca in combination with Tecentriq as first-line maintenance therapy for ES-SCLC in 4Q25 $106 • Growth driven by uptake in the 1LM setting • Opportunity to redefine the treatment paradigm in 1L maintenance • I
Slide 13: Research & Development
Research & Development Robert Iannone, M.D., M.S.C.E. Executive Vice President, Global Head of Research & Development, Chief Medical Officer 13 August 3, 2026
Slide 14: Progress Towards Realizing Full Potential of Zanidatamab
Progress Towards Realizing Full Potential of Zanidatamab Results from the Phase 3 HERIZON-GEA-01 Study Data Support Zanidatamab as the HER2-targeted Agent of Choice in 1L HER2+ GEA • Zanidatamab + tislelizumab provide benefit regardless of PD-L1 status with 26.4m mOS (+7 months vs. control arm) • Su
Slide 15: Key Pipeline Programs
Key Pipeline Programs Key Clinical Programs PHASE 1 PHASE 2 PHASE 3 PHASE 4 / REGULATORY Recent / Upcoming Milestones 1L GEA (HERIZON-GEA-01) Interim OS data expected 3Q26; PDUFA date of August 25, 2026 1L BTC (HERIZON-BTC-302) Breast cancer patients post T-DXd (EmpowHER-BC-303) Anticipate top-line
Slide 16: Financial Performance
Financial Performance Phil Johnson Executive Vice President, Chief Financial Officer 16 August 3, 2026
Slide 17: 2Q26 Financial Results
2Q26 Financial Results Continued Commercial Execution + Financial Discipline 2Q26 2Q25 Key Commentary • 16% increase primarily driven by higher Xywav, Modeyso, Total Revenues $1,208.3M $1,045.7M Epidiolex, and Zepzelca revenues Non-GAAP Gross Margin1 92.1% 92.7% • Slight decrease primarily due to ro
Slide 18: 2026 Financial Guidance
2026 Financial Guidance Raising Revenue and Updating Expense Guidance1 Updated 2026 Guidance Prior Guidance Key Commentary (as of August 3, 2026) (as of May 5, 2026) • Continue to expect double-digit growth for combined rare oncology + epilepsy revenue Total Revenues $4.60 - $4.75B $4.25 - $4.50B •
Slide 19: Closing
Closing Renee Gala President and Chief Executive Officer 19 August 3, 2026
Slide 20: Strong Momentum Into 2H26
Strong Momentum Into 2H26 Research and Commercial Corporate Development Development Zanidatamab Published HERIZON-GEA-01 data in Continued commercial execution The New England Journal of Medicine1 and data generation Identifying and Ready for launch in 1L GEA; pursuing opportunities PDUFA date of Au
Slide 21: Appendix
Appendix 0 Jazz Pharmaceuticals.
Slide 22: Glossary
Glossary Acronym Definition Acronym Definition 1L First-line IH Idiopathic hypersomnia 1LM First-line maintenance JME Juvenile myoclonic epilepsy 2L Second-line LGS Lennox-Gastaut Syndrome AG Authorized generic LPS Loss per share ANI Adjusted net income M Million ANL Adjusted net loss mOS Median ove
Slide 23: Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information1 Three Months Ended June 30, In millions, except per share amounts 2026 2025 (unaudited) Net Income Diluted EPS Net Loss Diluted LPS GAAP reported $192.8 $2.78 $(718.5) $(11.74) Intangible asset amortization 170.0 2.45 162.1 2.65 Share
Slide 24: Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information 1 Three Months Ended June 30, (In millions, except percentages) 2026 2025 GAAP gross margin on total revenues 90.4 % 88.9 % Acquisition accounting inventory fair value step-up 1.3 % 3.5 % Share-based compensation expense 0.4 % 0.3 % No
Slide 25: Reconciliation of GAAP to Non-GAAP Adjusted 2026 Guidance
Reconciliation of GAAP to Non-GAAP Adjusted 2026 Guidance 1 Projected Range (In millions, except percentages) Low High GAAP gross margin on total revenues 89 % 90 % Acquisition accounting inventory fair value step-up 1% 1% Non-GAAP gross margin on total revenues1 90 % 91 % GAAP SG&A expenses $1,506